Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759573 | 0.79 | CA12 (0.43) | ALDH1A1LMNACA12CA9GLS | |
| SCHEMBL31230279 | 0.78 | DRD3 (0.41) | DRD3ALDH1A1LMNACA12CA9 | |
| SCHEMBL14928448 | 0.78 | CYP1A2 (0.46) | DRD3ALDH1A1LMNACA12CA9 | |
| SCHEMBL17983217 | 0.76 | ALDH1A1 (0.45) | DRD3ALDH1A1CA12CA9GLS | |
| SCHEMBL17983100 | 0.75 | DRD3 (0.45) | DRD3ALDH1A1CA12CA9GLS | |
| SCHEMBL13919903 | 0.74 | ACHE (0.48) | DRD3ALDH1A1LMNAGLSKMT2A | |
| SCHEMBL21618327 | 0.74 | CA12 (0.44) | DRD3ALDH1A1LMNACA12CA9 | |
| SCHEMBL14909935 | 0.74 | ALDH1A1 (0.44) | DRD3ALDH1A1LMNACA12CA9 | |
| SCHEMBL10076112 | 0.74 | RPS6KA2 (0.42) | DRD3ALDH1A1LMNACA12CA9 | |
| SCHEMBL14842153 | 0.74 | ACHE (0.43) | DRD3ALDH1A1LMNACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | DRD3 957/4885ALDH1A1 1567/4885LMNA 4764/4885 |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | DRD3 957/4885ALDH1A1 1567/4885LMNA 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.